Jan 15, 2026
How did two‑dose NVX‑CoV2373 trial efficacy compare to single‑dose immunobridged approvals for variant‑updated vaccines?
Two well-controlled phase 3 trials of the recombinant protein vaccine NVX‑CoV2373 showed high clinical efficacy for a two‑dose primary series — about 89.7% against symptomatic COVID‑19 in the UK trial...